13.82 USD
▼-1.00-6.75%
盘后 13.62 -1.43%
2026-09-15
市值
$515.60M
市盈率
—
EPS
-1.72
股息率
—
52 周区间
8.60 – 17.79
成交量
704.61K
Beta
0.75
目标价
23.43
52W 低 8.6052W 高 17.79
价格走势
公司简介
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt...
关联新闻
- Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.